Search

Displaying results 3031 - 3040 of 10000 in total
  1. Drug

    Fenfluramine

    go.drugbank.com/drugs/DB00574
    ApprovedIllicitInvestigationalWithdrawn

    [A214694, A214718, A11906] Through its ability to modulate neurotransmission, fenfluramine has reemerged as an effective therapy against pharmacoresistant seizures, such as those involved in Dravet syndrome … [A214688, A214691, A214700] Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal; it was granted a new FDA approval on June 25, 2020, for treatment of patients with Dravet syndrome

    Categories: Serotonin 5-HT2 Receptor Agonists, Cytochrome P-450 SubstratesSynonyms: 1-(m-trifluoromethyl-phenyl)-2-ethylaminopropane
  2. Drug

    Taletrectinib

    go.drugbank.com/drugs/DB18711
    ApprovedInvestigational

    the secondary solvent-front mutation _G2032R_ is 400-times lower than that of the previously approved first-generation inhibitors [crizotinib] and [entrectinib]. … [A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523]

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Substrates
  3. Drug

    L-arginine

    go.drugbank.com/drugs/DB17289
    ApprovedInvestigationalNutraceutical

    Mixtures: Aminosyn II 7% M In 10% Dextrose(dual Chamber), Aminosyn II 8.5% M In 20% Dextrose (dual Chamber)
  4. Drug

    Idrapril

    go.drugbank.com/drugs/DB19598
    Experimental

    The usage of the INN stem '-pril' in the name indicates that Idrapril is a angiotensin-converting enzyme inhibitor. Idrapril has a monoisotopic molecular weight of 258.12 Da.

  5. Drug

    Rentiapril

    go.drugbank.com/drugs/DB20567
    Experimental

    The usage of the INN stem '-pril' in the name indicates that Rentiapril is a angiotensin-converting enzyme inhibitor. Rentiapril has a monoisotopic molecular weight of 313.04 Da.

  6. Drug

    Moveltipril

    go.drugbank.com/drugs/DB20917
    Experimental

    The usage of the INN stem '-pril' in the name indicates that Moveltipril is a angiotensin-converting enzyme inhibitor. Moveltipril has a monoisotopic molecular weight of 398.19 Da.

  7. Drug

    Ordesekimab

    go.drugbank.com/drugs/DB16649
    Investigational

    Ordesekimab is under investigation in clinical trial NCT02633020 (Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease).

  8. Drug

    Bromchlorenone

    go.drugbank.com/drugs/DB20459
    Experimental

    The usage of the INN stem '-renone' in the name indicates that Bromchlorenone is a mineralocorticoid receptor (MR, MCR, aldosterone receptor) antagonist. … Bromchlorenone has a monoisotopic molecular weight of 246.9 Da.

  9. Drug

    Unasnemab

    go.drugbank.com/drugs/DB18837
    Investigational

    Unasnemab is under investigation in clinical trial NCT04683848 (Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury).

  10. Drug

    PR1 leukemia peptide vaccine

    go.drugbank.com/drugs/DB15276
    Investigational

    PR1 leukemia peptide vaccine is under investigation in clinical trial NCT00513578 (Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome).